CCM
OXFD

Consonance Capital Management’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Consonance Capital Management’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,244,460
Closed -$11.5M – 41
2020
Q1 		$11.5M Sell
1,244,460
-1,119,264
-47% -$15.6M 0.86% 25
2019
Q4 		$39.2M Buy
2,363,724
+219,200
+10% +$3.55M 2.39% 18
2019
Q3 		$35.7M Sell
2,144,524
-199,000
-8% -$2.75M 3.53% 12
2019
Q2 		$32.2M Sell
2,343,524
-265,260
-10% -$4.06M 2.28% 16
2019
Q1 		$44.9M Buy
2,608,784
+29,000
+1% +$459K 2.84% 12
2018
Q4 		$33M Buy
2,579,784
+130,600
+5% +$1.98M 2.42% 14
2018
Q3 		$39.8M Buy
2,449,184
+110,000
+5% +$1.57M 2.14% 19
2018
Q2 		$30.2M Hold
2,339,184
– – 1.94% 21
2018
Q1 		$29.1M Buy
2,339,184
+1,219,297
+109% +$14.8M 2.66% 16
2017
Q4 		$15.6M Buy
+1,119,887
New +$16.4M 1.41% 18

Other funds holding OXFD

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Consonance Capital Management's OXFD Position: Q2 2020 in Review

Consonance Capital Management sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q2 2020, closing a stake of 1,244,460 shares — an estimated $11.5M sold.

Consonance Capital Management first reported a position in OXFD in Q4 2017 and held it in 10 quarters. The position peaked at $44.9M in Q1 2019. 65 funds tracked by Wall St. Rank hold OXFD as of Q2 2020.

  • Consonance Capital Management reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q2 2020 after selling out during the quarter.
  • Consonance Capital Management sold 1,244,460 Oxford Immunotec Global PLC Ordinary Shares shares in Q2 2020, an estimated $11.5M.
  • Consonance Capital Management first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2017 and held it in 10 quarters.
  • Consonance Capital Management's Oxford Immunotec Global PLC Ordinary Shares position peaked at $44.9M in Q1 2019.
  • 65 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q2 2020.

Based on Consonance Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.